MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

Phase 2

Recruiting

• Conditions: Refractory Multiple Myeloma; Relapse Multiple Myeloma
• Interventions: Drug: Teclistamab Monotherapy; Drug: Teclistamab

• Registration Number: NCT06171685
• Lead Sponsor: Multiple Myeloma Research Consortium

Brief Summary

This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol.

The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-11-03
• Study First Submitted QC: 2023-12-12
• Study First Posted: 2023-12-15
• Study Start: 2024-11-17
• Status Verified: 2025-01
• Last Update Submitted: 2025-07-10
• Last Update Posted: 2025-07-15
• Primary Completion: 2029-07-31
• Study Completion: 2030-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Sub-protocol A	Teclistamab Monotherapy	Serves as the reference arm for the platform
Sub-Protocol B	Teclistamab	This arm will be an investigational arm

Primary Outcome Measures

Name	Time	Method
ORR	through completion of the study, and yearly	Objective Response Rate

Trial Locations

Locations (13)

City of Hope; 🇺🇸 Duarte, California, United States

Emory Winship Cancer Center; 🇺🇸 Atlanta, Georgia, United States

University of Chicago Cancer Center; 🇺🇸 Chicago, Illinois, United States

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States

Dana Farber Cancer Institute/Harvard Medical School; 🇺🇸 Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Center; 🇺🇸 Detroit, Michigan, United States

Mayo Clinic Rochester; 🇺🇸 Rochester, Minnesota, United States

Washington University Medicine; 🇺🇸 St. Louis, Missouri, United States

Hackensack University Medical Center; 🇺🇸 Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Scroll for more (3 remaining)